Micardisplus

Telmisartan, one of the active ingredients in Micardisplus, is an Angiotensin II receptor blocker presented as a tablet for oral use. Combined with hydrochlorothiazide, it is indicated for the management of essential hypertension in adult patients, helping to effectively lower elevated blood pressure.

GNH USA supplies Micardisplus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support global distribution and ensure product integrity.

Micardisplus, an angiotensin II receptor blocker combined with a thiazide diuretic, is employed in the management of hypertension.

Essential hypertension: lowers systolic and diastolic blood pressure to target levels. Hypertension in type 2 diabetes: improves blood pressure control while offering renal protective effects. Hypertension with chronic kidney disease: reduces pressure load and may slow progression of renal impairment. High‑risk cardiovascular patients: contributes to reduction of cardiovascular events when combined with lifestyle measures. Patients requiring diuretic therapy: hydrochlorothiazide component promotes natriuresis, aiding fluid balance.

Micardisplus may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urination or nocturia - Electrolyte disturbances such as low potassium or sodium - Mild fatigue - Dry mouth

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue, or airway - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia leading to cardiac arrhythmia - Hepatic dysfunction with jaundice - Severe hypotension causing syncope

When prescribing Micardisplus, clinicians should observe several precautionary measures to ensure safe use.

Blood pressure monitoring: check regularly after initiation and dose changes. Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. Electrolyte surveillance: monitor serum potassium and sodium levels, especially with the diuretic component. Hepatic impairment: use with caution in patients with severe liver disease. Pregnancy and lactation: avoid use unless benefits outweigh risks; contraindicated in second and third trimester. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Micardisplus can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes): combined use may increase risk of renal dysfunction, hyperkalemia, and hypotension. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: concurrent use can raise lithium concentrations, requiring serum level monitoring. - ACE inhibitors or other ARBs: additive blood pressure lowering may lead to hypotension. - Other antihypertensive agents (beta‑blockers, calcium channel blockers): dose adjustments may be needed to avoid excessive hypotension.